C-REV (former name HF10) showed good safety and excellent anti-tumor effect in combination with chemotherapy on primary treatment of 6 Japanese patients with unresectable advanced pancreatic cancer. These are intermediate results of a Phase I study.

Takara Bio news release, January 15, 2018